The specialty pharmacy space has been in somewhat of a rut when it comes to M&A–but that won’t last, Moody’s says.
Look for specialty players to “return to more active M&A” going forward, SVP Michael Levesque wrote in the company’s recently released Healthcare Quarterly report. And look for them to snatch up more innovative drugs than they have in the past.
The reason? Politicians, the public and the media alike have been closely watching the sector’s M&A strategy over the past several months. You know the one, made famous by Valeant and Martin Shkreli’s Turing: Buy a product and immediately turn around and send its list price soaring.
It’s landed several others besides Valeant and Turing in trouble–see: Horizon, Mallinckrodt–and now specialty drugmakers, who typically made “limited investments in internal R&D,” are ready to change their ways, Levesque says.
Dublin drugmakers Jazz and Horizon have already spearheaded the movement, he points out, with their respective $1.5 billion pickup of Celator and $800 million acquisition of Raptor. “We anticipate more deals of this variety,” he wrote.
One specialty player who won’t be getting back in on the M&A action? Valeant. The Canadian drugmaker has pledged to stay away from the dealmaking table in an effort to get its debt–piled up sky-high after years of rampant dealmaking under former CEO J. Michael Pearson–under control. In the meantime, though, it hasn’t steered completely clear of price hikes: Earlier this year, the company announced it would be jacking some list prices up by between 2% and 9%.
By Carly Helfand
Source: Fierce Pharma
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
